Tumor suppressor genes are frequently targeted by PTC mutations in association with disease, and we have previously defined the readthrough efficiency in response to the aminoglycoside G418 of the PTCome of the PTEN tumor suppressor [26], which is mutated in somatic cancers and in the germline of patients with PHTS. This evidence concerns the gene PTEN and cancer.